Psilocybin (received from Usona Institute and NIDA Investigational Drug and Material Supply Program) and DOI (Sigma-Aldrich, cat #D101) were dissolved in saline to a concentration of 1 mg/ml. Ketanserin (Sigma-Aldrich, cat #S006) and SB242084 (Tocris, cat #2901) were dissolved in 10% DMSO to a concentration of 1 mg/ml. Solutions were prepared on the day of injection when possible and otherwise stored at −20°C for up to a month. All injections were intraperitoneal. The dosage of 1 mg/kg for Psilocybin and DOI has been shown to reliably elicit the head-twitch response, a behavioral marker of psychedelic activity [22 (link),25 (link)]. The chosen dose of Ketanserin abolishes the head-twitch responses produced by Psilocybin [22 (link)]. We selected a relatively high dose of SB242084, which has behavioral effects in decision-making tasks [26 ,27 (link)]. Saline, DOI or Psilocybin were injected 20 min before behavioral testing. Antagonist were injected 10 min before the main treatment (30 min prior to testing). Animals received multiple injections (min 1, max 4) given at least 2 weeks of washout between injections. Treatments were not repeated in the same animals and given in random order (Supplementary Table S1 ).
Psilocybin
Manufactured by Merck Group
Psilocybin is a chemical compound found in certain species of mushrooms. It is a naturally occurring psychoactive substance that has been used for centuries in various cultural and religious contexts. Psilocybin is considered a valuable tool for scientific research in areas such as psychology, neuroscience, and medicine.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using psilocybin
1
Pharmacological Modulation of Psychedelic Effects
2
Investigating Psychedelic-Induced Head Twitch
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Psilocybin (received from Usona Institute and NIDA Investigational Drug and Material Supply Program) and DOI (Sigma-Aldrich, cat #D101) were dissolved in saline to a concentration of 1 mg/ml. Ketanserin (Sigma-Aldrich, cat #S006) and SB242084 (Tocris, cat #2901) were dissolved in 10% DMSO to a concentration of 1 mg/ml. Solutions were prepared on the day of injection when possible and otherwise stored at −20 °C for up to a month. All injections were intraperitoneal. The dosage of 1 mg/kg for Psilocybin and DOI has been shown to reliably elicit the head-twitch response, a behavioral marker of psychedelic activity [23 (link), 26 (link)]. The chosen dose of Ketanserin abolishes the head-twitch responses produced by Psilocybin [23 (link)]. We selected a relatively high dose of SB242084, which has behavioral effects in decision-making tasks [27 (link), 28 (link)]. Saline, DOI or Psilocybin were injected 20 min before behavioral testing. Antagonist were injected 10 min before the main treatment (30 min prior to testing). Animals received multiple injections (min 1, max 4) and were given at least 2 weeks of washout between injections. Treatments were not repeated in the same animals and given in random order (Supplementary Table S2 ).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!